Takayuki Warisawa

Jun 20, 2023 | ahajournals.org | Takayuki Warisawa |Christopher Cook |Yousif Ahmad |James Howard

Originally publishedhttps://doi.org/10.1161/CIRCINTERVENTIONS.122.012700Circulation: Cardiovascular Interventions. 2023;16AbstractBackground:The majority of randomized controlled trials of revascularization decision-making excludes left main coronary artery disease (LMD). Therefore, contemporary clinical outcomes of patients with stable coronary artery disease and LMD with proven ischemia remain poorly understood.